Takeda Pharmaceutical (TKPHF) Common Equity (2018 - 2026)

Takeda Pharmaceutical's Common Equity history runs 9 years deep, the most recent figure standing at $49.6 billion for Q1 2026.

• In Q1 2026, Common Equity rose 9.05% year-over-year to $49.6 billion; the TTM figure through Mar 2026 stood at $49.6 billion (up 9.05% YoY), while the FY2026 annual figure was $51.6 billion, up 13.43% from the prior year.
• Common Equity was $49.6 billion for Q1 2026 at Takeda Pharmaceutical, roughly flat from $49.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $50.5 billion in Q2 2023 to a low of $43.7 billion in Q4 2022.
• Historically, Common Equity has averaged $48.2 billion across 5 years, with a median of $48.8 billion in 2022.
• The sharpest annual moves came in 2025 and 2026: Common Equity slipped 7.38% in 2025, then gained 9.05% in 2026.
• A 5-year view of Common Equity shows it stood at $43.7 billion in 2022, then grew by 4.34% to $45.6 billion in 2023, then increased by 6.98% to $48.8 billion in 2024, then grew by 1.78% to $49.7 billion in 2025, then retreated by 0.19% to $49.6 billion in 2026.
• The last three Common Equity figures came in at $49.6 billion (Q1 2026), $49.7 billion (Q4 2025), and $48.4 billion (Q3 2025), per Business Quant data.